Observational studyPediatric pulmonology2026
Clinical Outcomes Associated With Long-Acting Beta Agonist Escalation in Preschool Children With Severe Asthma: A Retrospective Hospital Based Clinic Cohort Study.
Observational study in Pediatric pulmonology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe define adherent, difficult-to-treat asthma as 'true severe asthma.' In preschool children, evidence for add-on long-acting beta-agonists (LABA) to inhaled corticosteroids (ICS) in those with persistent uncontrolled disease despite high-dose ICS remains limited. We evaluated clinical outcomes of ICS-LABA therapy in this population.
methodsThis retrospective observational study (2021-2024) included children aged 6-72 months with severe, uncontrolled asthma despite medium- to high-dose ICS and verified adherence, who were initiated on LABA therapy. Primary outcomes were severe exacerbations (systemic corticosteroid use, hospitalizations, and uncontrolled symptoms). Secondary outcomes included PICU admissions and spontaneously reported adverse events. Outcomes 6 months before and after LABA initiation were compared using generalized estimating equations (GEE), adjusting for seasonality, age, sex, and atopy.
resultsFifty-three children were included (mean age 38.8 ± 17.6 months, 41.5% male, atopy 49.1%). LABA initiation was associated with a substantial reduction in clinical burden: hospitalizations declined from 41.5% to 3.8% (p < 0.001), systemic corticosteroid use from 86.8% to 52.8% (p < 0.001), and daily symptoms from 86.8% to 37.7% (p < 0.001). PICU admissions decreased from 9.4% to 0%. These associations remained significant after adjustment for covariates (p < 0.001). No adverse events were spontaneously reported by patients or caregivers during the follow-up period; however, systematic adverse event surveillance was not conducted.
conclusionIn adherent preschool children with true severe asthma, LABA initiation was associated with observed improvements in clinical outcomes. Still, prospective controlled studies with systematic safety surveillance are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.